Abstract:Neurodegenerative diseases (NDDs), including Alzheimer's disease (AD) and Parkinson's disease (PD), affect the ageing population worldwide and while severely impairing the quality of life of millions, they also cause a massive economic burden to countries with progressively ageing populations. Parallel with the search for biomarkers for early detection and prediction, the pursuit for therapeutic approaches has become growingly intensive in recent years. Various prospective therapeutic approaches have been explored with an emphasis on early prevention and protection, including, but not limited to, gene therapy, stem cell therapy, immunotherapy and radiotherapy. Many pharmacological interventions have proved to be promising novel avenues, but successful applications are often hampered by the poor delivery of the therapeutics across the blood-brain-barrier (BBB). To overcome this challenge, nanoparticle (NP)-mediated drug delivery has been considered as a promising option, as NP-based drug delivery systems can be functionalized to target specific cell surface receptors and to achieve controlled and long-term release of therapeutics to the target tissue. The usefulness of NPs for loading and delivering of drugs has been extensively studied in the context of NDDs, and their biological efficacy has been demonstrated in numerous preclinical animal models. Efforts have also been made towards the development of NPs which can be used for targeting the BBB and various cell types in the brain. The main focus of this review is to briefly discuss the advantages of functionalized NPs as promising theranostic agents for the diagnosis and therapy of NDDs. We also summarize the results of diverse studies that specifically investigated the usage of different NPs for the treatment of NDDs, with a specific emphasis on AD and PD, and the associated pathophysiological changes. Finally, we offer perspectives on the existing challenges of using NPs as theranostic agents and possible futuristic approaches to improve them.

Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective

An Overview on Global Trends in Nanotechnological Approaches for Alzheimer Therapy.

Nanomedicine: A Promising Way to Manage Alzheimer’s Disease

Nanomedicines in the Management of Alzheimer's Disease: Current View and Future Prospects.

Nanomaterials for the treatment and diagnosis of Alzheimer's disease: An overview

Alzheimer's Disease Pathology and Assistive Nanotheranostic Approaches for Its Therapeutic Interventions

Application of nanotechnology for diagnosis of Alzheimer's disease

Nanotheranostic Applications for Detection and Targeting Neurodegenerative Diseases

Functional Nanomaterials for the Diagnosis of Alzheimer's Disease: Recent Progress and Future Perspectives

Nanoparticle formulations in the diagnosis and therapy of Alzheimer's disease

Nanomedicine in Alzheimer’s Therapy: Enhancing Drug Delivery Strategies

Designing and Formulation of Nanocarriers for “Alzheimer’s and Parkinson’s” Early Detection and Therapy

Development of Nanomedicines for the Treatment of Alzheimer's Disease: Raison d'être, Strategies, Challenges and Regulatory Aspects

Nanotheranostic agents for neurodegenerative diseases

A Nanotechnological Approach to the Management of Alzheimer Disease and Type 2 Diabetes

Emerging nanotechnology for Alzheimer's disease: From detection to treatment

Recent Progress in Nanomedicine for the Diagnosis and Treatment of Alzheimer's Diseases

Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease

Nanocrystals: a new herald for the management of Alzheimer's disease

Nanomaterials Toward the Treatment of Alzheimer’s Disease:Recent Advances and Future Trends

Recent advances in nanotechnology for combating Alzheimer's disease